跳至主要内容
临床试验/JPRN-jRCTs051200135
JPRN-jRCTs051200135招募中4 期

Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients with Cancer - ONCO PE trial

Ono Koh0 个研究点目标入组 330 人开始时间: 2021年2月16日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 80age old(—)
性别
All

入选标准

  • 1. Patients with active cancer (solid and hematologic malignancies) presenting with objectively newly confirmed PE who are scheduled to be treated by anticoagulation therapy.
  • 2. Patients with an simplified PESI score of 1 or less

排除标准

  • 1. Contraindicated patients for rivaroxaban (Clinically significant liver disease, Bacterial endocarditis, Active bleeding, Inadequate contraceptive measures if of childbearing potential, Concomitant use of strong cytochrome P-450 3A4 inhibitors or inducers or P-glycoprotein inhibitors or inducers, etc)
  • 2. Expected life expectancy <6 months
  • 3. Patients who do not provide written informed consent.
  • 4. Patients who judged to be inappropriate for enrolment by the physician (including patients at a high risk of gastrointestinal or genitourinary bleeding)

研究者

发起方
Ono Koh

相似试验

Optimal Duration of Anticoagulation Therapy for... | 临床试验